Printer Friendly

SYNERGEN APPOINTS NATIONAL SALES MANAGER

 SYNERGEN APPOINTS NATIONAL SALES MANAGER
 BOULDER, Colo., May 4 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN)


announced today the appointment of R. Michael Smullen as national sales manager. This new position reflects the company's commitment to building a sales force in the United States to market Synergen products.
 Based at company headquarters in Boulder, Smullen initially will be involved in the strategic planning and design for the sales force. This will include the design of sales force regional and territory alignments and integration of sales into the early process of drug development. As Synergen's first product, ANTRIL(TM) for sepsis syndrome, gets closer to receiving an FDA license for marketing, Smullen will recruit regional sales managers and begin to build the field sales force.
 Smullen joins Synergen from Fujisawa Pharmaceutical Co., where he held management positions at the district, division, regional and national level. At Fujisawa, Smullen was involved in the launch of a third generation
cephalosporin for serious and life-threatening infections. Previously Smullen held sales positions at SmithKline &


French and Boehringer Ingelheim pharmaceutical companies.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein based pharmaceuticals. The company's research is targeted toward products to treat inflammatory diseases, chronic ulcers and neurological diseases. Synergen's lead product, ANTRIL, is in clinical testing for seven indications including sepsis syndrome, rheumatoid arthritis and graft vs. host disease.
 -0- 5/4/92
 /CONTACT: Debra Catz Bannister of Synergen, 303-938-6242/
 (SYGN) CO: Synergen Inc. ST: Colorado IN: MTC SU: PER


MC-BB -- DV001 -- 5809 05/04/92 08:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:256
Previous Article:LEADING RESEARCHERS PRESENT PRECLINICAL RESULTS WITH THE LIPOSOME COMPANY'S TCL C-53
Next Article:ROCKWELL INTERNATIONAL, HONEYWELL TEAM TO PURSUE MINUTEMAN III GUIDANCE REPLACEMENT PROGRAM


Related Articles
SYNERGEN FILES REGISTRATION STATEMENT FOR 3,000,000 SHARES OF COMMON STOCK
SYNERGEN REVISES PARTNERSHIP OFFER
SYNERGEN EXPANDS INTO EUROPE
SYNERGEN APPOINTS DIRECTOR OF QUALITY
SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
SYNERGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
SYNERGEN COMPLETES BUYOUT OF R&D PARTNERSHIP
SYNERGEN APPOINTS VICE PRESIDENTS OF MARKETING AND SALES AND PROCESS ENGINEERING
SYNERGEN REPORTS MANAGEMENT CHANGES
SYNERGEN APPOINTS GREGORY ABBOTT CHIEF EXECUTIVE OFFICER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters